News
Phico Therapeutics gains £13.1m grant to advance antibacterial therapy
Cambridge, UK-based Phico Therapeutics has been awarded a grant of up to £13.2m ($18.2m) to take its lead antibacterial therapy through Phase I clinical trials.
You're using an outdated browser. To get the most out of this website, as well as many others, please consider upgrading to a modern browser, such as Google Chrome, Mozilla Firefox, or Microsoft Edge.
Cambridge, UK-based Phico Therapeutics has been awarded a grant of up to £13.2m ($18.2m) to take its lead antibacterial therapy through Phase I clinical trials.